Effects of an Air Bolus on Primary Peristalsis
The Role of Swallowing An Air Bolus on Primary Esophageal Peristalsis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Procedures and Analyses
- All the study subjects are required to be without oral food or fluid intake for at least 3 hours prior to the study
- After application of local lidocaine, the high resolution manometry (HRM) catheter will be inserted through the more patent nares and positioned such that it covers the pharynx and the esophagus. Affixed to the high resolution catheter will be a single lumen, end-hole catheter (length: 90 cm, outside diameter: 1.58 mm) wherein the end hole of the tube will be secured at a fixed pharyngeal site on the HRM catheter and the other end of the tube will be connected to a stopcock so that the tube may be either open or closed to atmospheric pressure.
- Study subjects will be asked to swallow their ambient saliva ten times with the stopcock open and ten times with the stopcock closed. There is a 30 second interval between swallows.
- Following completion of the study, the manometry catheter and the single lumen tube will be removed.
- The participant will also be instructed to resume their regular diet and activity.
- All the pressure recordings will be analyzed by two individuals in a blinded fashion.
The investigators will compare motility pressure metrics like striated esophageal muscle contractile integral, esophageal smooth muscle contractile integral, peristaltic wave velocity and esophageal clearance time to evaluate the potential differences in esophageal motility metrics when an air bolus is allowed to flow into the esophagus compared to those metrics when air is shunted out of the pharynx by a trans-nasal tube vented to the atmosphere.
Statistical analysis will be performed in a repeated measures technique comparing metrics with and without the pharyngeal shunt stopcock closed.
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Reza Shaker, MD
- Phone Number: 4149556840
- Email: rshaker@mcw.edu
Study Contact Backup
- Name: Mark Kern
- Phone Number: 4148053826
- Email: mkern@mcw.edu
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53086
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female subject with no history or present diagnosis of pharyngo-esophageal diseases or motility disorders
- Age 21 to 90 years
Exclusion Criteria:
- Under the age of 21
- Over the age of 90
- Presence of pharyngo-esophageal disease or motility disorders
- Pregnancy
- Lidocaine allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Healthy adults
Pharyngo-esophageal high resolution manometry with affixed single-lumen, end-hole catheter wherein one end of the single lumen catheter is in the pharynx and the other is connected to an external stopcock to vent or not vent the pharynx to atmosphere during twenty dry swallows (10 vented, 10 unvented).
|
The high resolution manometry (HRM) catheter will be inserted through the more patent nares and positioned such that it covers the pharynx and the esophagus.
Affixed to the high resolution catheter will be a single lumen, end-hole catheter (length: 90 cm, outside diameter: 1.58 mm) wherein the end hole of the tube will be secured at a fixed pharyngeal site on the HRM catheter and the other end of the tube will be connected to a stopcock so that the tube may be either open or closed to atmospheric pressure.
3. Study subjects will be asked to swallow their ambient saliva ten times with the stopcock open and ten times with the stopcock closed.
There is a 30 second interval between swallows.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
striated esophageal muscle contractile integral
Time Frame: through study completion, an average of 1 year
|
Motility pressure metric to measure contractile vigor of the proximal esophagus in mmHg-cm-seconds
|
through study completion, an average of 1 year
|
|
smooth esophageal muscle contractile integral
Time Frame: through study completion, an average of 1 year
|
Motility pressure metric to measure contractile vigor of the distal esophagus in mmHg-cm-seconds
|
through study completion, an average of 1 year
|
|
peristaltic wave velocity
Time Frame: through study completion, an average of 1 year
|
average speed at which the primary peristaltic pressure wave traverses the esophagus in cm/second
|
through study completion, an average of 1 year
|
|
esophageal clearance time
Time Frame: through study completion, an average of 1 year
|
time for the entire swallowed bolus to travers the esophagus in seconds
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PRO00035855
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.